Nivolumab Monotherapy for Various Tumor Types
Pan Tumor Rollover Study
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,500 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
You may be able to join if
- I have signed a consent form.
- I am eligible for continued treatment based on my previous study results.
- I am on hold for treatment after a long-lasting response.
- I agree to use contraception if I am a sexually active woman or man.
You may not be able to join if
- I do not meet the eligibility criteria from my previous study.
- I am not benefiting from the current treatment as assessed by my doctor.
- I have an adverse event or illness that makes participation unsafe.
- Other criteria in the study rules out my participation.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityMain Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Loading trial locations…
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT